TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04399746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: 6mg once daily in day 0,1,7 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500mg once daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 400 IU twice daily for 30 days
Study: NCT02078076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cardiac Imaging (with Gadolinium)
Study: NCT01376440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: household water treatment
Description: household water treatment with 1.25% sodium hypochlorite
Study: NCT02513147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PI
Description: (Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 NRTI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 NRTI
Study: NCT02734901

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400 g frozen raspberries
Description: 1x daily intake of 600 mL red raspberry beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 g frozen raspberries
Description: 1x daily intake of 600 mL red raspberry beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1x daily intake of 600 mL raspberry deprived supplement
Study: NCT01133990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820
Description: E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
Study: NCT00744354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Intravenous infusion, 30mg/m2, Day 4, each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
Study: NCT01931631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat, low-Glycemic Index, vegan diet
Description: Low-fat, low-Glycemic Index, vegan diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADA diet
Description: Diet in accordance with the American Diabetes Association
Study: NCT02173262

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Study: NCT00159497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: porous coated Trilogy®
Description: THA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy Calcicoat®
Description: THA
Study: NCT02698995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the same analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the same analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the same analgesia protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the same analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the same analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the same analgesia protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
Study: NCT01830023

Intervention type: DEVICE
Intervention: cardiac ultrasound examination
Description: cardiac ultrasound examination to examine the vitality
Study: NCT02149771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemoembolization
Description: Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemoembolization
Description: Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular stents implantation
Description: Bare stents implant within portal vein.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iodine-125 seed strand implantation
Description: Iodine-125 seed strand implant within portal vein.
Study: NCT01993095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based, DVD-delivered physical activity
Description: Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Usual care/Wait list
Description: Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
Study: NCT02541383

Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
Description: Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab
Description: Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16mg/kg every 8 weeks for 2 years
Study: NCT04959071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum assisted closure VAC vs conventional dressing
Description: In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum assisted closure VAC vs conventional dressing
Description: In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily.
Study: NCT05577273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)
Description: single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
Study: NCT01280201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
Study: NCT01779076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30% oxygen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Study: NCT00393094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: 125 mg/m\^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m\^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
Study: NCT04607473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automated breast ultrasound (ABUS)
Description: Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
Study: NCT02342184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-0998
Study: NCT00652925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Higher dose, 6 mg/kg/dose BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Active drug at lower dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Control comparator, 15 mg/kg/dy target dose
Study: NCT03124030

Intervention type: PROCEDURE
Intervention: simple dental extraction
Description: dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied

Intervention type: PROCEDURE
Intervention: simple dental extraction
Description: dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
Study: NCT00925340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up
Description: The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
Study: NCT02712840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze-All Protocol
Description: All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Protocol
Description: Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
Study: NCT04256590

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
Study: NCT03869060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Description: Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
Study: NCT03111758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow augmentation
Description: Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow augmentation
Description: Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
Study: NCT02329990

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phosphorus
Description: phosphorus supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phosphorus
Description: phosphorus supplement
Study: NCT03335891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: Volunteers received an asthma education program and trained for diaphragmatic, pursed lip breathing exercises as well as participated in the core stabilization exercises program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises
Study: NCT01454180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.
Description: * Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI
Description: * Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.
Study: NCT02201940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once daily
Study: NCT01948752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition information on menus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition information on menus
Study: NCT01294527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless cardiac stimulator implant to pace the left ventricle for CRT
Description: Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
Study: NCT03149627

Intervention type: OTHER
Intervention: Estimates - prevalence of lifetime/chronic HBV infection
Description: Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
Study: NCT01398878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention work shift
Description: Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
Study: NCT04663672

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No-Scent Control
Description: Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
Study: NCT03016676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
Study: NCT01948752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition information on menus
Study: NCT01261676

Intervention type: OTHER
Intervention: Implementation aids
Description: An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)

Intervention type: OTHER
Intervention: Implementation aids
Description: An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)